Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus

Coronaviruses as possible cross-species viruses have caused several epidemics. The ongoing emergency of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has posed severe threats to the global economy and public health, which has generated great concerns about zoonotic viruses. Swine acute di...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 23; no. 19; p. 11250
Main Authors Chen, Yangzhen, You, Yecheng, Wang, Shuqi, Jiang, Lin, Tian, Lili, Zhu, Shaozhou, An, Xiaoping, Song, Lihua, Tong, Yigang, Fan, Huahao
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2022
MDPI
Subjects
Acids
Antiviral agents
antiviral drugs
coronavirus
Coronaviruses
COVID-19
Cytotoxicity
Dengue fever
Diarrhea
Disease transmission
Drug development
Drug screening
Drug therapy
Drugs
Economic impact
Epidemics
Gemcitabine
Gene expression
Global economy
Infections
Methylene blue
Mycophenolate mofetil
Mycophenolic acid
Pandemics
Public health
SADS-CoV
Severe acute respiratory syndrome coronavirus 2
Swine
Vaccines
Viral diseases
Viruses
Online AccessGet full text

Cover

More Information
Summary:Coronaviruses as possible cross-species viruses have caused several epidemics. The ongoing emergency of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has posed severe threats to the global economy and public health, which has generated great concerns about zoonotic viruses. Swine acute diarrhea syndrome coronavirus (SADS-CoV), an alpha-coronavirus, was responsible for mass piglet deaths, resulting in unprecedented economic losses, and no approved drugs or vaccines are currently available for SADS-CoV infection. Given its potential ability to cause cross-species infection, it is essential to develop specific antiviral drugs and vaccines against SADS-CoV. Drug screening was performed on a total of 3523 compound-containing drug libraries as a strategy of existing medications repurposing. We identified five compounds (gemcitabine, mycophenolate mofetil, mycophenolic acid, methylene blue and cepharanthine) exhibiting inhibitory effects against SADS-CoV in a dose-dependent manner. Cepharanthine and methylene blue were confirmed to block viral entry, and gemcitabine, mycophenolate mofetil, mycophenolic acid and methylene blue could inhibit viral replication after SADS-CoV entry. This is the first report on SADS-CoV drug screening, and we found five compounds from drug libraries to be potential anti-SADS-CoV drugs, supporting the development of antiviral drugs for a possible outbreak of SADS-CoV in the future.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms231911250